Clinical trials
Completed Phase 1 trials in South Africa
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
152 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 6 |
| 2010 | 6 |
| 2011 | 10 |
| 2012 | 6 |
| 2013 | 10 |
| 2014 | 7 |
| 2015 | 9 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 8 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 8 |
| 2022 | 13 |
| 2023 | 11 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 152 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 14 |
| GlaxoSmithKline | 8 |
| Cycle Pharmaceuticals Ltd. | 6 |
| Hoffmann-La Roche | 6 |
| Boehringer Ingelheim | 5 |
| Merck Sharp & Dohme LLC | 5 |
| Aeras | 4 |
| HIV Vaccine Trials Network | 4 |
| Janssen Research & Development, LLC | 4 |
| Novo Nordisk A/S | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| HIV Infections | 29 |
| Tuberculosis | 16 |
| Acquired Immunodeficiency Syndrome | 6 |
| COVID-19 | 6 |
| Diabetes Mellitus, Type 2 | 6 |
| Diabetes Mellitus | 5 |
| Melanoma | 5 |
| Bacterial Infections | 3 |
| Hemophilia A | 3 |
| Neoplasms | 3 |
Trials
Showing 1 to 25 of 152. Each trial links to its page on Pharma Observatory.
52 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.